Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
Andrieu GP, Kohn M, Simonin M, Smith CL, Cieslak A, Dourthe MÉ, Charbonnier G, Graux C, Huguet F, Lhéritier V, Dombret H, Spicuglia S, Rousselot P, Boissel N, Asnafi V. Andrieu GP, et al. Blood. 2021 Nov 11;138(19):1855-1869. doi: 10.1182/blood.2020010081. Blood. 2021. PMID: 34125178 Free PMC article. Clinical Trial.
Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation.
Cieslak A, Charbonnier G, Tesio M, Mathieu EL, Belhocine M, Touzart A, Smith C, Hypolite G, Andrieu GP, Martens JHA, Janssen-Megens E, Gut M, Gut I, Boissel N, Petit A, Puthier D, Macintyre E, Stunnenberg HG, Spicuglia S, Asnafi V. Cieslak A, et al. Among authors: andrieu gp. J Exp Med. 2020 Sep 7;217(9):e20192360. doi: 10.1084/jem.20192360. J Exp Med. 2020. PMID: 32667968 Free PMC article.
Adenylate kinase 2 expression and addiction in T-ALL.
Maslah N, Latiri M, Asnafi V, Féroul M, Bedjaoui N, Steimlé T, Six E, Verhoyen E, Macintyre E, Lagresle-Peyrou C, Lhermitte L, Andrieu GP. Maslah N, et al. Among authors: andrieu gp. Blood Adv. 2021 Feb 9;5(3):700-710. doi: 10.1182/bloodadvances.2020002700. Blood Adv. 2021. PMID: 33560378 Free PMC article.
Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
Simonin M, Schmidt A, Bontoux C, Dourthe MÉ, Lengliné E, Andrieu GP, Lhermitte L, Graux C, Grardel N, Cayuela JM, Huguet F, Arnoux I, Ducassou S, Macintyre E, Gandemer V, Dombret H, Petit A, Ifrah N, Baruchel A, Boissel N, Asnafi V. Simonin M, et al. Among authors: andrieu gp. J Hematol Oncol. 2021 May 3;14(1):74. doi: 10.1186/s13045-021-01068-4. J Hematol Oncol. 2021. PMID: 33941203 Free PMC article.
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup.
Touzart A, Mayakonda A, Smith C, Hey J, Toth R, Cieslak A, Andrieu GP, Tran Quang C, Latiri M, Ghysdael J, Spicuglia S, Dombret H, Ifrah N, Macintyre E, Lutsik P, Boissel N, Plass C, Asnafi V. Touzart A, et al. Among authors: andrieu gp. Sci Transl Med. 2021 May 26;13(595):eabc4834. doi: 10.1126/scitranslmed.abc4834. Sci Transl Med. 2021. PMID: 34039737 Free article. Clinical Trial.
Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL.
Simonin M, Andrieu GP, Birsen R, Balsat M, Hypolite G, Courtois L, Graux C, Grardel N, Cayuela JM, Huguet F, Chalandon Y, Le Bris Y, Macintyre E, Gandemer V, Petit A, Rousselot P, Baruchel A, Bouscary D, Hermine O, Boissel N, Asnafi V. Simonin M, et al. Among authors: andrieu gp. Blood. 2023 Mar 16;141(11):1353-1358. doi: 10.1182/blood.2022017755. Blood. 2023. PMID: 36599110 Free article. No abstract available.
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V. Smith C, et al. Among authors: andrieu gp. Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x. Mol Cancer. 2023. PMID: 36650499 Free PMC article.
32 results